首页> 外文期刊>Stem Cell Research & Therapy >Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model
【24h】

Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model

机译:在啮齿动物中风模型中,与脐带间充质基质细胞相比,人脐带血单个核细胞的动脉内移植更有效,更安全

获取原文
           

摘要

Introduction Stroke is the second leading cause of death worldwide, claims six lives every 60 seconds, and is a leading cause of adult disability across the globe. Tissue plasminogen activator, the only United States Food and Drug Administration (FDA)-approved drug currently available, has a narrow therapeutic time window of less than 5 hours. In the past decade, cells derived from the human umbilical cord (HUC) have emerged as a potential therapeutic alternative for stroke; however, the most effective HUC-derived cell population remains unknown. Methods We compared three cell populations derived from the human umbilical cord: cord blood mononuclear cells (cbMNCs); cord blood mesenchymal stromal cells (cbMSCs), a subpopulation of cbMNCs; and cord matrix MSCs (cmMSCs). We characterized these cells in vitro with flow cytometry and assessed the cells’ in vivo efficacy in a 2-hour transient middle cerebral artery occlusion (MCAo) rat model of stroke. cbMNCs, cbMSCs, and cmMSCs were each transplanted intraarterially at 24 hours after stroke. Results A reduction in neurologic deficit and infarct area was observed in all three cell groups; however, this reduction was significantly enhanced in the cbMNC group compared with the cmMSC group. At 2 weeks after stroke, human nuclei-positive cells were present in the ischemic hemispheres of immunocompetent stroke rats in all three cell groups. Significantly decreased expression of rat brain-derived neurotrophic factor mRNA was observed in the ischemic hemispheres of all three cell-treated and phosphate-buffered saline (PBS) group animals compared with sham animals, although the decrease was least in cbMNC-treated animals. Significantly decreased expression of rat interleukin (IL)-2 mRNA and IL-6 mRNA was seen only in the cbMSC group. Notably, more severe complications (death, eye inflammation) were observed in the cmMSC group compared with the cbMNC and cbMSC groups. Conclusions All three tested cell types promoted recovery after stroke, but cbMNCs showed enhanced recovery and fewer complications compared with cmMSCs.
机译:简介中风是全球第二大死亡原因,每60秒可导致六人死亡,并且是全球成人残疾的主要原因。组织纤维蛋白溶酶原激活剂是目前唯一获得美国食品和药物管理局(FDA)批准的药物,其治疗时间窗少于5小时。在过去的十年中,源自人脐带(HUC)的细胞已成为中风的潜在治疗替代方法。但是,最有效的HUC来源的细胞群体仍然未知。方法我们比较了来自人脐带的三种细胞群:脐带血单核细胞(cbMNCs);脐带血单核细胞(cbMNCs)。脐血间充质基质细胞(cbMSC),cbMNC的亚群;和脐带基质MSC(cmMSC)。我们使用流式细胞仪对这些细胞进行了体外表征,并在2小时的短暂性脑中动脉阻塞(MCAo)大鼠中风模型中评估了这些细胞的体内功效。在卒中后24小时,将cbMNC,cbMSC和cmMSC分别进行动脉内移植。结果在所有三个细胞组中均观察到神经功能缺损和梗塞面积的减少。但是,与cmMSC组相比,cbMNC组的这种降低明显增强。中风后2周,在所有三个细胞组中,具有免疫功能的中风大鼠的缺血半球中均存在人核阳性细胞。与假手术动物相比,在所有三个细胞处理和磷酸盐缓冲盐水(PBS)组动物的缺血半球中均观察到大鼠脑源性神经营养因子mRNA的表达显着降低,尽管降幅在cbMNC处理动物中最小。仅在cbMSC组中观察到大鼠白介素(IL)-2 mRNA和IL-6 mRNA的表达显着降低。值得注意的是,与cbMNC和cbMSC组相比,cmMSC组的并发症更为严重(死亡,眼睛发炎)。结论所有三种测试的细胞类型均促进中风后的恢复,但与cmMSC相比,cbMNCs显示出增强的恢复且并发症更少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号